development of foxy5, a wnt5a mimicking peptide, in gi cancers
Published 2 weeks ago • 90 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
2:14
neofox: foxy-5, a wnt5a mimicking peptide, in stage ii/iii colon cancer
-
1:54
intensified dosing of neoadjuvant foxy-5 for colon cancer in the neofox trial
-
2:13
immune microenvironment evolution in breast cancer brain metastases
-
1:45
association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...
-
3:56
the use of the immunoscore in predicting the outcome of neoadjuvant chemotherapy in gi cancer
-
0:55
prognostic biomarkers of immunotherapy efficacy in breast cancer
-
2:03
preoperative management of operable ct3 cn1 luminal breast cancer: upfront neoadjuvant chemotherapy
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
2:51
$102.2 million for new pelotonia immuno-oncology institute
-
2:51
breast cancer: extended adjuvant therapy and cost factors
-
5:03
consideration for neoadjuvant treatment in her2 invasive ductal carcinoma
-
1:46
atf5 and hif1: targets for esophageal cancer therapy
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
1:27
n-of-one working with intermountain
-
2:24
wavelinq™ endoavf patient selection – u.s. only – chapter 9 – training summary
-
21:07
recognizing wpoi-5 teaching module by dr. margaret brandwein
-
1:32
stem cell transplants: dr. joseph antin | dana-farber cancer institute
-
12:46
b-mogen biotechnologies